溴隐亭对成年型糖尿病的作用。
Effect of bromocriptine on maturity onset diabetes.
作者信息
Barnett A H, Chapman C, Gailer K, Hayter C J
出版信息
Postgrad Med J. 1980 Jan;56(651):11-4. doi: 10.1136/pgmj.56.651.11.
Abstract
The effect of the dopamine agonist, bromocriptine, and the dopamine antagonist, metoclopramide, on glucose tolerance was examined in maturity onset diabetics and normal subjects. After bromocriptine there was a lowered fasting blood glucose and improved glucose tolerance in the diabetics. The controls showed an initial improvement in glucose tolerance. A reduction in insulin levels and a marked fall in plasma prolactin was observed in all subjects. Growth hormone concentrations were low and unaffected in the diabetics, and there was an inconsistent rise in the normals. After metoclopramide there was some impairment in glucose tolerance in the normal subjects, but this was not significant in the diabetics. There was also a marked prolactin release in all subjects, but no significant effect on insulin or growth hormone. It is concluded that bromocriptine lowers the blood glucose and improves glucose tolerance in maturity onset diabetics. This action may be the result of the lowered prolactin which occurred without a concomitant rise in growth hormone.
摘要
在成年型糖尿病患者和正常受试者中，研究了多巴胺激动剂溴隐亭和多巴胺拮抗剂甲氧氯普胺对葡萄糖耐量的影响。服用溴隐亭后，糖尿病患者的空腹血糖降低，葡萄糖耐量改善。对照组的葡萄糖耐量最初有所改善。所有受试者的胰岛素水平均降低，血浆催乳素显著下降。糖尿病患者的生长激素浓度较低且未受影响，正常受试者的生长激素浓度则有不一致的升高。服用甲氧氯普胺后，正常受试者的葡萄糖耐量出现一定程度的损害，但在糖尿病患者中并不显著。所有受试者的催乳素也有明显释放，但对胰岛素或生长激素无显著影响。得出的结论是，溴隐亭可降低成年型糖尿病患者的血糖并改善葡萄糖耐量。这一作用可能是催乳素降低的结果，且生长激素并未随之升高。
相似文献
1
Effect of bromocriptine on maturity onset diabetes.溴隐亭对成年型糖尿病的作用。
Postgrad Med J. 1980 Jan;56(651):11-4. doi: 10.1136/pgmj.56.651.11.
2
The effects of prolonged bromocriptine administration on PRL secretion GH and glycaemic control in stable insulin-dependent diabetes mellitus.长期服用溴隐亭对稳定型胰岛素依赖型糖尿病患者催乳素分泌、生长激素及血糖控制的影响。
Clin Endocrinol (Oxf). 1983 Feb;18(2):179-85. doi: 10.1111/j.1365-2265.1983.tb03200.x.
3
The effect of bromocriptine on insulin secretion and glucose tolerance in patients with acromegaly.溴隐亭对肢端肥大症患者胰岛素分泌及糖耐量的影响。
Clin Endocrinol (Oxf). 1981 Nov;15(5):473-8. doi: 10.1111/j.1365-2265.1981.tb00690.x.
4
Treatment of acromegaly with bromocriptine.
Aust N Z J Med. 1979 Jun;9(3):225-32. doi: 10.1111/j.1445-5994.1979.tb04128.x.
5
Growth hormone, insulin, and prolactin secretion in anorexia nervosa and obesity during bromocriptine treatment.溴隐亭治疗期间神经性厌食症和肥胖症患者生长激素、胰岛素及催乳素的分泌情况
Br Med J. 1977 Jul 16;2(6080):156-9. doi: 10.1136/bmj.2.6080.156.
6
Variation of blood glucose and serum growth hormone, prolactin and insulin in subjects with insulin-dependent diabetes, after OGTT and pretreatment with 2-Br-alpha-ergocryptine.
Acta Diabetol Lat. 1977 May-Aug;14(3-4):119-28. doi: 10.1007/BF02581399.
7
[Action of bromocriptine on glucose metabolism in diabetics].[溴隐亭对糖尿病患者葡萄糖代谢的作用]
Sem Hop. 1977;53(34-35):1857-62.
8
[Effect of oral administration of 2-bromo-alpha-ergocriptine on blood glucose, serum IRI and HGH levels in normal subjects and diabetics (author's transl)].口服2-溴-α-麦角隐亭对正常人和糖尿病患者血糖、血清胰岛素释放免疫活性物质（IRI）及人生长激素（HGH）水平的影响（作者译）
Nihon Naibunpi Gakkai Zasshi. 1977 Jun 20;53(6):743-51. doi: 10.1507/endocrine1927.53.6_743.
9
Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion.
Clin Investig. 1993 May;71(5):372-8. doi: 10.1007/BF00186626.
10
[Effect of caerulein on blood glucose, serum insulin, glucagon, prolactin and growth hormone before and after oral glucose load in healthy volunteers and diabetic patients (author's transl)].[蛙皮素对健康志愿者和糖尿病患者口服葡萄糖负荷前后血糖、血清胰岛素、胰高血糖素、催乳素及生长激素的影响（作者译）]
Klin Wochenschr. 1981 Jun 1;59(11):539-43. doi: 10.1007/BF01716454.
引用本文的文献
1
Bromocriptine in type 2 diabetes: a promising alternative, a systematic review and meta-analysis.溴隐亭治疗2型糖尿病：一种有前景的替代疗法，一项系统评价和荟萃分析。
Cardiovasc Diabetol Endocrinol Rep. 2025 May 26;11(1):10. doi: 10.1186/s40842-025-00222-y.
2
Evidence for dopamine production and distribution of dopamine D2 receptors in the equine gastrointestinal mucosa and pancreas.在马的胃肠道黏膜和胰腺中存在多巴胺产生和多巴胺 D2 受体分布的证据。
PLoS One. 2024 Feb 27;19(2):e0298660. doi: 10.1371/journal.pone.0298660. eCollection 2024.
3
Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes.多巴胺在葡萄糖稳态调节、2型糖尿病发病机制及多巴胺活性/代谢受损的慢性病症中的作用：对病理生理及治疗目的的意义
Biomedicines. 2023 Nov 7;11(11):2993. doi: 10.3390/biomedicines11112993.
4
Dopamine 2 agonists for the management of type 2 diabetes: a systematic review and meta-analysis.用于治疗2型糖尿病的多巴胺2激动剂：一项系统评价和荟萃分析。
J Diabetes Metab Disord. 2023 May 12;22(2):931-943. doi: 10.1007/s40200-023-01230-4. eCollection 2023 Dec.
5
The role of Neurochemicals, Stress Hormones and Immune System in the Positive Feedback Loops between Diabetes, Obesity and Depression.神经递质、应激激素和免疫系统在糖尿病、肥胖症和抑郁症之间的正反馈循环中的作用。
Front Endocrinol (Lausanne). 2023 Aug 17;14:1224612. doi: 10.3389/fendo.2023.1224612. eCollection 2023.
6
Serotonin and Dopamine Mimic Glucose-Induced Reinforcement in : Potential Role of NSM Neurons and the Serotonin Subtype 4 Receptor.血清素和多巴胺模拟葡萄糖诱导的强化作用：NSM神经元和血清素4型受体的潜在作用
Front Physiol. 2021 Dec 20;12:783359. doi: 10.3389/fphys.2021.783359. eCollection 2021.
7
Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes.溴隐亭作为一种潜在的降糖药物用于治疗伴有2型糖尿病的泌乳素瘤。
Intern Med. 2019 Nov 1;58(21):3125-3128. doi: 10.2169/internalmedicine.2755-19. Epub 2019 Jun 27.
8
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.目前用于 2 型糖尿病的药物的药理学和治疗意义。
Nat Rev Endocrinol. 2016 Oct;12(10):566-92. doi: 10.1038/nrendo.2016.86. Epub 2016 Jun 24.
9
Bromocriptine inhibits adipogenesis and lipogenesis by agonistic action on α2-adrenergic receptor in 3T3-L1 adipocyte cells.溴隐亭通过在 3T3-L1 脂肪细胞上激动α2-肾上腺素能受体抑制脂肪生成和脂生成。
Mol Biol Rep. 2013 May;40(5):3783-92. doi: 10.1007/s11033-012-2455-5. Epub 2012 Dec 28.
10
Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics.
Experientia. 1992 Mar 15;48(3):248-53. doi: 10.1007/BF01930467.
本文引用的文献
1
Effects of 2-Br-alpha-Ergocryptine, L-dopa and cyclic imides on serum prolactin in postmenopausal women.2-溴-α-麦角隐亭、左旋多巴和环状酰亚胺对绝经后妇女血清催乳素的影响。
Eur J Cancer (1965). 1973 Sep;9(9):657-64. doi: 10.1016/0014-2964(73)90008-x.
2
The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine).CB - 154（2 - 溴 - α - 麦角隐亭）对人体催乳素分泌的抑制作用。
J Clin Endocrinol Metab. 1972 Nov;35(5):768-71. doi: 10.1210/jcem-35-5-768.
3
The acute effect of 2-bromo-a-ergocryptine (CB-154) on anterior pituitary hormones and free fatty acids in man.
Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):281-3.
4
Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine.正常人和肢端肥大症患者在给予2-溴-α-麦角隐亭后血浆生长激素水平的变化
J Clin Endocrinol Metab. 1975 Mar;40(3):363-6. doi: 10.1210/jcem-40-3-363.
5
Bromocriptine treatment of acromegaly.溴隐亭治疗肢端肥大症。
Br Med J. 1975 Feb 8;1(5953):299-303. doi: 10.1136/bmj.1.5953.299.
6
Intracellular glucopenia causes prolactin release in man.细胞内葡萄糖减少会导致人体释放催乳素。
J Clin Endocrinol Metab. 1977 Sep;45(3):377-83. doi: 10.1210/jcem-45-3-377.
7
Prolactin: a diabetogenic hormone.催乳素：一种致糖尿病激素。
Diabetologia. 1977 Apr;13(2):99-104. doi: 10.1007/BF00745135.
8
Variation of blood glucose and serum growth hormone, prolactin and insulin in subjects with insulin-dependent diabetes, after OGTT and pretreatment with 2-Br-alpha-ergocryptine.
Acta Diabetol Lat. 1977 May-Aug;14(3-4):119-28. doi: 10.1007/BF02581399.
Zotero 插件